Key facts
- Kimialys’s last known valuation is $3.2M (Apr 2023).
- It has raised $5.4M; the latest was Later Stage VC ($4.2M) in Dec 2025.
- Notable investors include Agoranov, Super Capital, GO Capital, Turenne Groupe, Angels Santé — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Kimialys
- ·The full record, as it builds
Funding rounds
No funding rounds for Kimialys are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kimialys
Developer of customized biofunctionalized nanoparticles and surfaces designed to improve the performance of in vitro diagnostics. The company provides coated gold nanoparticles, biochips, and contract development services to optimize assay performance and detection reliability, enabling assay developers, point of care test developers, and pharmaceutical laboratories to improve rapid test and in vitro analysis accuracy while lowering development and production costs.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2020
- Employees
- 26
- Website
- kimialys.com/
- Ownership
- Privately Held (backing)
Kimialys doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kimialys shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kimialys in its N-PORT filings yet. We sweep new filings monthly.